Company Overview and News
ESPOO, Finland, Oct. 05, 2018 (GLOBE NEWSWIRE) -- Qt today announced that Peugeot – the French car brand – has selected Qt’s development framework as the foundation for the digital cockpit inside the PEUGEOT e-LEGEND CONCEPT.
LONDON, Aug 21 — Under the presidency of Donald Trump, the US is using sanctions against its adversaries — and even some friends — like never before. The latest batch against Russia and Turkey sank emerging markets, with stocks poised for their worst month since January 2016.
FP UG DDAIF
PARIS (July 27): French carmaker Renault achieved record profitability in the first half of the year, but currency and raw material costs weighed on its bottom line, with analysts suggesting it had been eclipsed by domestic rival PSA Group.
Good morning, ladies and gentlemen, and welcome. Welcome to this 2018 H1 Group PSA financial results announcement session. We know that you are very busy people and therefore we value your time. Thank you for your interest in the PSA Group.
BEIJING, July 6 — Ford Motor’s China slump intensified, with vehicle sales tumbling 38 per cent in June and the automaker recording its worst-ever first half, as buyers shunned its aging models that are awaiting overhauls and flocked to rivals.
HYUO TM UG TYT KIMTY TOYOF HYUD KIMTF 7203 HYUP GM
Ford Motor’s China slump intensified, with vehicle sales tumbling 38 percent in June and the automaker recording its worst-ever first half, as buyers shunned its aging models that are awaiting overhauls and flocked to rivals.
HYUO TM UG TYT KIMTY TOYOF HYUD KIMTF 7203 HYUP GM
Per Reuters, Volkswagen AG (VLKAY - Free Report) plans to close its Germany-based Wolfsburg factory for one to two days per week, between August and September. During the production halt, the company will deal with problems caused by engine emission tests. Except for Wolfsburg hub, facilities at Zwickau and Emden will also remain closed for a few days.
VLKAF VC UG DDAIF VLKAY
Volkswagen AG’s (VLKAY - Free Report) Audi AG has agreed on a deal with Hyundai Motor Company to develop fuel-cell technology. Subject to approval from regulatory authorities, both the companies will team up to develop hydrogen vehicle technology to facilitate volume production in a quicker and efficient way.
VLKAF HYUO TM UG 7203 TYT HYUP TOYOF VLKAY HYUD
BERLIN—When the U.S. ambassador to Germany, Richard Grenell, returns to Washington for consultation with the administration Wednesday, he will be carrying a peace offering for President Donald Trump from Germany’s leading auto makers.
VLKAF UG GM RNO DDAIF
Toyota Motor Corporation (TM - Free Report) announced that it has decided to team up with ALBERT Inc. to analyze big data for the advancement of automated driving technology. Additionally, Toyota is expected to invest ¥400 million in ALBERT and is likely to acquire new shares of the company through a third-party share allocation dated May 30, 2018.
HD VC TM UG 7203 TYT MSFT TOYOF ADC
Shares of Meritor, Inc. (MTOR - Free Report) gained roughly 1.9% in a day’s trading, following its second-quarter fiscal 2018 earnings release. The company recorded adjusted earnings of 75 cents per share in second-quarter fiscal 2018 (ended Mar 31, 2018) compared with 35 cents a year ago. The figure comfortably surpassed the Zacks Consensus Estimate of 65 cents.
AUY YRI UG MTOR ALSN LVS
ZHANGJIAKOU, China (Reuters) - While auto workers in Germany and South Korea fight to save their jobs, one of China’s youngest auto brands is gearing up to build sport utility vehicles at a new factory with digitally-connected robots and a fresh workforce of 1,800 people.
GELYF UG GELYY DDAIF 0175 ABB ABLZF GM ROK
2018-10-01 - Asif
Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...
2018-09-25 - Asif
Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...
Silicon Investor Message Boards
This table lists all message boards related to EPA:UG / PEUGEOT on message board site Silicon Investor.